Department of Medicine, Division of Hospital Internal Medicine & Division of Geriatric Medicine and Gerontology, Mayo Clinic, Rochester, Minnesota, USA
Department of Medicine, Division of Hospital Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
BMJ Case Rep. 2021 Mar 25;14(3):e241793. doi: 10.1136/bcr-2021-241793.
A 54-year-old woman presented with pruritic rash and hives of 3 days' duration followed by shortness of breath for 1 day. SARS-CoV-2 PCR test for COVID-19 was positive. Cutaneous manifestations of COVID-19 include acral lesions, urticarial rash, erythematous maculopapular rash, vascular rashes and vesicular rash. The cutaneous manifestations are mostly described as self-limiting. Urticarial rashes are not reported as the initial presentation symptom of COVID-19 infection but mostly noted to occur at the same time or after the onset of non-cutaneous symptoms. Management of cutaneous manifestations of COVID-19 affecting quality of life has not been well studied. Antihistamine therapy is the primary recommended therapy. Role of antiviral therapy for severe cases of rash needs to be further assessed.
一位 54 岁女性因瘙痒性皮疹和荨麻疹就诊,病程为 3 天,随后出现呼吸急促 1 天。SARS-CoV-2 PCR 检测 COVID-19 呈阳性。COVID-19 的皮肤表现包括肢端皮损、荨麻疹、红斑性斑丘疹、血管性皮疹和水疱性皮疹。皮肤表现大多被描述为自限性。荨麻疹皮疹不作为 COVID-19 感染的初始表现症状,但大多被注意到与非皮肤症状同时或之后发生。对影响生活质量的 COVID-19 皮肤表现的治疗尚未得到充分研究。抗组胺治疗是主要推荐的治疗方法。对于严重皮疹病例的抗病毒治疗的作用需要进一步评估。